In the general population, maternal SARS-CoV-2 infection during pregnancy is associated with worse maternal outcomes; however, only one study so far has evaluated COVID-19 clinical outcomes in pregnant and postpartum women with multiple sclerosis, showing no higher risk for poor COVID-19 outcomes in these patients.
Objective:
In this multicenter study, we aimed to evaluate COVID-19 clinical outcomes in pregnant patients with multiple sclerosis.
Methods:
We recruited 85 pregnant patients with multiple sclerosis who contracted COVID-19 after conception and were prospectively followed-up in Italian and Turkish Centers, in the period 2020-2022. A control group of 1354 women was extracted from the database of the Multiple Sclerosis and COVID-19 (MuSC-19). Univariate and subsequent logistic regression models were fitted to search for risk factors associated with severe COVID-19 course (at least one outcome among hospitalization, intensive care unit [ICU] admission and death).
Results:
In the multivariable analysis, independent predictors of severe COVID-19 were age, body mass index ⩾ 30, treatment with anti-CD20 and recent use of methylprednisolone. Vaccination before infection was a protective factor. Vaccination before infection was a protective factor. Pregnancy was not a risk nor a protective factor for severe COVID-19 course.
Conclusion:
Our data show no significant increase of severe COVID-19 outcomes in patients with multiple sclerosis who contracted the infection during pregnancy.
AdamD. The pandemic’s true death toll: Millions more than official counts. Nature2022; 601(7893): 312–315.
2.
Abu-RayaBMichalskiCSadaranganiM, et al. Maternal immunological adaptation during normal pregnancy. Front Immunol2020; 11: 575197.
3.
GovindAEssienSKarthikeyanA, et al. Re: Novel coronavirus COVID-19 in late pregnancy: Outcomes of first nine cases in an inner city London hospital. Eur J Obstet Gynecol Reprod Biol2020; 251: 272–274.
4.
LapinskySE. Acute respiratory failure in pregnancy. Obstet Med2015; 8(3): 126–132.
5.
MetzTDCliftonRGHughesBL, et al. Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications. JAMA2022; 327(8): 748–759.
6.
PathirathnaMLSamarasekaraBPPDasanayakeTS, et al. Adverse perinatal outcomes in COVID-19 infected pregnant women: A systematic review and meta-analysis. Healthcare2022; 10(2): 203.
7.
NormanMNavérLSöderlingJ, et al. Association of maternal SARS-CoV-2 infection in pregnancy with neonatal outcomes. JAMA2021; 325(20): 2076–2086.
HoutchensMKEdwardsNCSchneiderG, et al. Pregnancy rates and outcomes in women with and without MS in the United States. Neurology2018; 91(17): e1559–e1569.
10.
NguyenALHavrdovaEKHorakovaD, et al. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. Mult Scler Relat Disord2019; 28: 235–243.
11.
SalterACrossAHCutterGR, et al. COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes. Mult Scler Relat Disord2022; 65: 104028.
12.
YamCJokubaitisVHellwigK, et al. MS, pregnancy and COVID-19. Mult Scler J2020; 26(10): 1137–1146.
13.
SormaniMPde RossiNSchiavettiI, et al. Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol2021; 89(4): 780–789.
14.
McDonaldWICompstonAEdanG, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol2001; 50(1): 121–127.
15.
PolmanCHReingoldSCEdanG, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald criteria.”Ann Neurol2005; 58(6): 840–846.
16.
PolmanCHReingoldSCBanwellB, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol2011; 69(2): 292–302.
17.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
18.
NuttallFQ. Body mass index: Obesity, BMI, and health: A critical review. Nutr Today2015; 50(3): 117–128.
19.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology1983; 33(11): 1444–1452.
20.
MaghbooliZHosseinpourHFattahiMR, et al. Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection. Mult Scler Relat Disord2022; 67: 104067.
21.
LonginettiEBowerHMcKayKA, et al. COVID-19 clinical outcomes and DMT of MS patients and population-based controls. Ann Clin Transl Neurol2022; 9: 1449–1458.
22.
SalterAFoxRJNewsomeSD, et al. Outcomes and risk factors associated with SARS-CoV-2 infection in a North American Registry of patients with multiple sclerosis. JAMA Neurol2021; 78(6): 699–708.
23.
CollinJByströmECarnahanAS, et al. Public Health Agency of Sweden’s brief report: Pregnant and postpartum women with severe acute respiratory syndrome coronavirus 2 infection in intensive care in Sweden. Acta Obstet Gynecol Scand2020; 99(7): 819–822.
24.
KnightMBunchKVousdenN, et al. Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: National population based cohort study. BMJ2020; 369: m2107.
25.
EllingtonSStridPTongVT, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status — United States, January 22–June 7, 2020. Morb Mortal Wkly Rep2020; 69(25): 769–775.
26.
JamiesonDJRasmussenSA. An update on COVID-19 and pregnancy. Am J Obstet Gynecol2022; 226(2): 177–186.
27.
CampbellKHTornatoreJMLawrenceKE, et al. Prevalence of SARS-CoV-2 among patients admitted for childbirth in southern Connecticut. JAMA2020; 323(24): 2520–2522.
28.
SuttonDFuchsKD’AltonM, et al. Universal screening for SARS-CoV-2 in women admitted for delivery. New Engl J Med2020; 382(22): 2163–2164.
29.
KoJYDeSistoCLSimeoneRM, et al. Adverse pregnancy outcomes, maternal complications, and severe illness among US delivery hospitalizations with and without a coronavirus disease 2019 (COVID-19) diagnosis. Clin Infect Dis2021; 73: S24–S31.
30.
KönigMTorgautenHMTranTT, et al. Immunogenicity and safety of a third SARS-CoV-2 vaccine dose in patients with multiple sclerosis and weak immune response after COVID-19 vaccination. JAMA Neurol2022; 79(3): 307–309.
31.
Centers for Disease Control and Prevention (CDC). COVID-19 vaccination program interim playbook for jurisdiction operations. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention (CDC), 2020.
32.
DickARosenbloomJIGutman-IdoE, et al. Safety of SARS-CoV-2 vaccination during pregnancy-obstetric outcomes from a large cohort study. BMC Pregnancy Childbirth2022; 22(1): 166.
33.
ShimabukuroTTKimSYMyersTR, et al. On preliminary findings of mRNA COVID-19 vaccine safety in pregnant persons. New Engl J Med2021; 384(16): 2273–2282.
34.
TheilerRNWickMMehtaR, et al. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. Am J Obstet Gynecol MFM2021; 3(6): 100467.
35.
BlakewayHPrasadSKalafatE, et al. COVID-19 vaccination during pregnancy: Coverage and safety. Am J Obstet Gynecol2022; 226(2): 236.e1–236.e14.
36.
WainstockTYolesISergienkoR, et al. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. Vaccine2021; 39(41): 6037–6040.
